Cost-Effectiveness of Hib Vaccination in Belarus and Uzbekistan
Author Information
Author(s): Ulla K. Griffiths, Andrew Clark, Veronika Shimanovich, Irina Glinskaya, Dilorom Tursunova, Lucia Kim, Liudmila Mosina, Rana Hajjeh, Karen Edmond
Primary Institution: Hib Initiative, London School of Hygiene and Tropical Medicine, London, United Kingdom
Hypothesis
This study aims to estimate and compare the cost-effectiveness of Hib vaccination in Belarus and Uzbekistan.
Conclusion
The Hib vaccine is considered cost-effective in both Belarus and Uzbekistan, with more favorable values in Uzbekistan due to higher mortality rates and lower vaccine costs.
Supporting Evidence
- The vaccine is estimated to prevent 467 invasive disease cases in Belarus and 3,069 in Uzbekistan.
- Cost per discounted DALY averted is US$ 9,323 in Belarus and US$ 267 in Uzbekistan.
- The vaccine is more cost-effective in Uzbekistan due to a higher baseline mortality burden.
Takeaway
This study looks at how much it costs to prevent diseases with a vaccine in two countries, finding that it's cheaper and more effective in Uzbekistan than in Belarus.
Methodology
A decision analytic model was used to estimate morbidity and mortality from Hib disease with and without the vaccine, using national data sources.
Limitations
The study faces uncertainty in disease-specific parameters, particularly for pneumonia, and uses a static model that may not reflect changes in disease dynamics over time.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website